Table 2 Use of medications, agiographic findings, and procedural results of the study population according to the AIP quartiles
Variable | Q1 | Q2 | Q3 | Q4 | P value | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
n = 199 | n = 200 | n = 200 | n = 199 | Overall | Q2 vs. Q1 * | Q3 vs. Q1 * | Q3 vs. Q2 * | Q4 vs. Q1 * | Q4 vs. Q2 * | Q4 vs. Q3 * | |
Medications before admission | |||||||||||
 Aspirin, n (%) | 145 (72.9) | 149 (74.5) | 154 (77.0) | 146 (73.4) | 0.784 | – | – | – | – | – | – |
 P2Y12 inhibitors, n (%) | 81 (40.7) | 81 (40.5) | 74 (37.0) | 80 (40.2) | 0.858 | – | – | – | – | – | – |
 Statins, n (%) | 150 (75.4) | 143 (71.5) | 155 (77.5) | 142 (71.4) | 0.418 | – | – | – | – | – | – |
 ACEIs/ARBs, n (%) | 55 (27.6) | 65 (32.5) | 72 (36.0) | 69 (34.7) | 0.300 | – | – | – | – | – | – |
 β-blockers, n (%) | 70 (35.2) | 79 (39.5) | 93 (46.5) | 63 (31.7) | 0.016 | 0.372 | 0.021 | 0.157 | 0.457 | 0.102 | 0.002 |
 Insulin, n (%) | 75 (37.7) | 73 (36.5) | 79 (39.5) | 63 (31.7) | 0.406 | – | – | – | – | – | – |
 Oral antidiabetic agents, n (%) | 89 (44.7) | 98 (49.0) | 110 (55.0) | 90 (45.2) | 0.145 | – | – | – | – | – | – |
Intraoperative anticoagulants | |||||||||||
 Unfractionated heparin, n (%) | 168 (84.4) | 170 (85.0) | 154 (77.0) | 156 (78.4) | 0.086 | – | – | – | – | – | – |
 LMWH, n (%) | 6 (3.0) | 7 (3.5) | 16 (8.0) | 10 (5.0) | 0.089 | – | – | – | – | – | – |
 Bivalirudin, n (%) | 25 (12.6) | 23 (11.5) | 30 (15.0) | 33 (16.6) | 0.448 | – | – | – | – | – | – |
Perioperative medications | |||||||||||
 Aspirin, n (%) | 196 (98.5) | 198 (99.0) | 200 (100.0) | 196 (98.5) | 0.308 | – | – | – | – | – | – |
 P2Y12 inhibitors, n (%) | 199 (100.0) | 200 (100.0) | 200 (100.0) | 199 (100.0) | – | – | – | – | – | – | – |
 GP IIb/IIIa receptor antagonist, n (%) | 29 (14.6) | 38 (19.0) | 45 (22.5) | 37 (18.6) | 0.246 | – | – | – | – | – | – |
Medications at discharge | |||||||||||
 Aspirin, n (%) | 196 (98.5) | 198 (99.0) | 200 (100.0) | 196 (98.5) | 0.308 | – | – | – | – | – | – |
 Cilostazol, n (%) | 3 (1.5) | 2 (1.0) | 1 (0.5) | 4 (2.0) | 0.473 | – | – | – | – | – | – |
 Clopidogrel, n (%) | 174 (87.4) | 183 (91.5) | 178 (89.0) | 190 (95.5) | 0.031 | 0.186 | 0.628 | 0.399 | 0.004 | 0.108 | 0.016 |
 Ticagrelor, n (%) | 25 (12.6) | 17 (8.5) | 22 (11.0) | 9 (4.5) | 0.031 | 0.186 | 0.628 | 0.399 | 0.004 | 0.108 | 0.016 |
 Statins, n (%) | 199 (100.0) | 200 (100.0) | 200 (100.0) | 199 (100.0) | – | – | – | – | – | – | – |
 ACEIs/ARBs, n (%) | 81 (40.7) | 93 (46.5) | 105 (52.5) | 121 (60.8) | 0.001 | 0.243 | 0.018 | 0.230 | < 0.001 | 0.004 | 0.094 |
 β-blockers, n (%) | 138 (69.3) | 147 (73.5) | 155 (77.5) | 136 (68.3) | 0.155 | – | – | – | – | – | – |
 Insulin, n (%) | 65 (32.7) | 76 (38.0) | 72 (36.0) | 57 (28.6) | 0.213 | – | – | – | – | – | – |
 Oral antidiabetic agents, n (%) | 87 (43.7) | 120 (60.0) | 119 (59.5) | 105 (52.8) | 0.003 | 0.001 | 0.002 | 0.919 | 0.071 | 0.145 | 0.175 |
Angiographic findings | |||||||||||
 One-vessel disease, n (%) | 22 (11.1) | 15 (7.5) | 18 (9.0) | 25 (12.6) | 0.347 | – | – | – | – | – | – |
 Two-vessel disease, n (%) | 68 (34.2) | 41 (20.5) | 42 (21.0) | 46 (23.1) | 0.004 | 0.002 | 0.003 | 0.902 | 0.015 | 0.527 | 0.610 |
 LM/three-vessel disease, n (%) | 109 (54.8) | 144 (72.0) | 140 (70.0) | 128 (64.3) | 0.001 | < 0.001 | 0.002 | 0.659 | 0.052 | 0.100 | 0.227 |
 Proximal LAD stenosis, n (%) | 94(47.2) | 110 (55.0) | 97 (48.5) | 100 (50.3) | 0.428 | – | – | – | – | – | – |
 Restenotic lesions, n (%) | 26 (13.1) | 26 (13.0) | 30 (15.0) | 29 (14.6) | 0.913 | – | – | – | – | – | – |
 Trifurcation or bifurcation lesions, n (%) | 155 (77.9) | 162 (81.0) | 151 (75.5) | 148 (74.4) | 0.403 | – | – | – | – | – | – |
 Chronic total occlusions, n (%) | 36 (18.1) | 46 (23.0) | 44 (22.0) | 57 (28.6) | 0.093 | – | – | – | – | – | – |
 Thrombus lesions, n (%) | 7 (3.5) | 14 (7.0) | 12 (6.0) | 12 (6.0) | 0.478 | – | – | – | – | – | – |
 Heavy calcification lesions, n (%) | 75 (37.7) | 69 (34.5) | 73 (36.5) | 48 (24.1) | 0.016 | 0.507 | 0.806 | 0.676 | 0.003 | 0.023 | 0.007 |
 Lesions > 20 mm long, n (%) | 108 (54.3) | 112 (56.0) | 122 (61.0) | 117 (58.8) | 0.537 | – | – | – | – | – | – |
Procedural results | |||||||||||
 Target vessel territory | |||||||||||
 LM, n (%) | 13 (6.5) | 16 (8.0) | 9 (4.5) | 18 (9.0) | 0.313 | – | – | – | – | – | – |
 LAD, n (%) | 104 (52.3) | 97 (48.5) | 100 (50.0) | 99 (49.7) | 0.899 | – | – | – | – | – | – |
 LCX, n (%) | 64 (32.2) | 69 (34.5) | 42 (21.0) | 48 (24.1) | 0.007 | 0.620 | 0.012 | 0.003 | 0.075 | 0.023 | 0.456 |
 RCA, n (%) | 69 (34.7) | 82 (41.0) | 100 (50.0) | 74 (37.2) | 0.011 | 0.193 | 0.002 | 0.071 | 0.601 | 0.435 | 0.010 |
 DES use, n (%) | 174 (87.4) | 172 (86.0) | 161 (80.5) | 159 (79.9) | 0.097 | – | – | – | – | – | – |
 BRS use, n (%) | 6 (3.0) | 7 (3.5) | 8 (4.0) | 11 (5.5) | 0.607 | – | – | – | – | – | – |
 DCB use, n (%) | 12 (6.0) | 11 (5.5) | 19 (9.5) | 14 (7.0) | 0.409 | – | – | – | – | – | – |
Complete revascularization, n (%) | 136 (68.3) | 115 (57.5) | 110 (55.0) | 107 (53.8) | 0.012 | 0.025 | 0.006 | 0.614 | 0.003 | 0.453 | 0.805 |